EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Endocrine Disruptors, Gut Microbiota, and Type 2 Diabetes: Bridging Mechanisms to Probiotic-Based Therapeutic Approaches

Shun-Man Cheung, Chi-Yung Cheng iD, Vinoth Kumar Ponnusamy, Kai-Fan Tsai iD, Chia-Te Kung, Wan-Ting Huang, Huey-Ling You, Shau-Hsuan Li iD, Wen-Chin Lee, Fu-Jen Cheng iD, Venkata Chaithanya iD

Diabetes, Metabolic Syndrome and Obesity · 2026-10 · Volume 19 · 1-21

DOI: 10.2147/dmso.s636877 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2026-10. Verfasst von Shun-Man Cheung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, Taitung MacKay Memorial Hospital, Taitung, Taiwan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic and lifestyle factors alone cannot explain the rising global burden of type 2 diabetes mellitus (T2DM). Growing evidence implicates endocrine-disrupting chemicals (EDCs) found in plastics, pesticides, food packaging, industrial products, and contaminated water as significant environmental contributors to metabolic dysfunction. EDCs, including bisphenol A (BPA), phthalates, per- and polyfluoroalkyl substances (PFAS), persistent organic pollutants (POPs), and heavy metals, have been associated with insulin resistance, pancreatic β-cell dysfunction, oxidative stress, mitochondrial impairment, chronic inflammation, and epigenetic modifications that collectively promote T2DM pathogenesis. The gut microbiota has emerged as a potential mediator of EDC-associated metabolic disruption, whereby chemical exposures may alter microbial diversity, disturb the Firmicutes/Bacteroidetes ratio, impair short-chain fatty acid production, decrease intestinal barrier integrity, driving metabolic endotoxemia and systemic inflammation. This narrative review examines the major EDCs associated with diabetes, their molecular and metabolic mechanisms of action, and their interactions with the gut microbiota, drawing on current experimental and epidemiological evidence. Special emphasis is placed on probiotic supplementation as an emerging therapeutic strategy targeting the EDC-gut microbiota-metabolic axis. Current evidence for probiotics in EDC-associated metabolic dysfunction is predominantly preclinical, with studies suggesting improvements in microbial homeostasis, pancreatic oxidative damage, and glucose metabolism. However, available evidence remains heterogeneous and human clinical trials specifically examining probiotic intervention in EDC-exposed populations at risk of T2DM remain absent, representing a fundamental translational gap that future research must urgently address. Advancing precision medicine approaches, integrating microbiome profiling, metabolomics, epigenetic analysis, and coordinated efforts across toxicology, clinical medicine, and public health, will be essential to reducing the growing global burden of environmentally driven type 2 diabetes.

Schlagwörter

Stichwörter der Autor:innen

bisphenol aendocrine-disrupting chemicalsgut microbiotaprobioticstype 2 diabetes mellitus

Autor:innen und Institutionen

  • Department of Physical Medicine and Rehabilitation, Taitung MacKay Memorial Hospital, Taitung, Taiwan.
  • Department of Emergency Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Department of Medicinal and Applied Chemistry, Kaohsiung Medical University (KMU), Kaohsiung, Taiwan.
  • Research Center for Precision Environmental Medicine, Kaohsiung Medical University (KMU), Kaohsiung, Taiwan.
  • Department of Medical Research, Kaohsiung Medical University Hospital (KMUH), Kaohsiung, Taiwan.
  • Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

ORCID-Profile: Chi-Yung Cheng, Kai-Fan Tsai, Shau-Hsuan Li, Fu-Jen Cheng, Venkata Chaithanya

Zitieren

APA

Cheung, S. M., Cheng, C. Y., Ponnusamy, V. K., Tsai, K. F., Kung, C. T., Huang, W. T., You, H. L., Li, S. H., Lee, W. C., Cheng, F. J., & Chaithanya, V. (2026). Endocrine Disruptors, Gut Microbiota, and Type 2 Diabetes: Bridging Mechanisms to Probiotic-Based Therapeutic Approaches. Diabetes, Metabolic Syndrome and Obesity, Volume 19, 1-21. https://doi.org/10.2147/dmso.s636877

Vancouver

Cheung SM, Cheng CY, Ponnusamy VK, Tsai KF, Kung CT, Huang WT, et al. Endocrine Disruptors, Gut Microbiota, and Type 2 Diabetes: Bridging Mechanisms to Probiotic-Based Therapeutic Approaches. Diabetes, Metabolic Syndrome and Obesity. 2026;Volume 19:1-21. doi:10.2147/dmso.s636877

BibTeX
@article{Cheung2026,
  author = {Cheung, Shun-Man and Cheng, Chi-Yung and Ponnusamy, Vinoth Kumar and Tsai, Kai-Fan and Kung, Chia-Te and Huang, Wan-Ting and You, Huey-Ling and Li, Shau-Hsuan and Lee, Wen-Chin and Cheng, Fu-Jen and Chaithanya, Venkata},
  title = {Endocrine Disruptors, Gut Microbiota, and Type 2 Diabetes: Bridging Mechanisms to Probiotic-Based Therapeutic Approaches},
  journal = {Diabetes, Metabolic Syndrome and Obesity},
  year = {2026},
  volume = {Volume 19},
  pages = {1--21},
  doi = {10.2147/dmso.s636877}
}
Kostenlos starten →